Background: Cerebrovascular stroke (CVS) is a common cause of death and disability. The C-reactive protein increases in response to stroke and may be used as a predictor for stroke outcome. We intended in this study to evaluate the role of serum CRP in predicting outcomes in CVS.
Introduction
Although Cerebro-vascular stroke is one of the leading causes of death and disability in the elderly [1] , indicators predicting outcomes in such patients have not been clearly delineated.
Acute stroke may trigger an inflammatory response that leads to increased levels of CRP [2] . This relationship between inflammation and atherosclerosis makes CRP a potential prognostic marker after vascular events and a potential predictor of Table 1 The main items of the NIHSS.
Instructions
Scale definition Score 1a. Level of consciousness: 0 = Alert 1 = Not alert; but arousable by minor stimulation to obey, answer, or respond 2 = Not alert; requires repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (not stereotyped) 3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid, and are flexic . . .. . ... 
Best gaze:
Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements will be scored, but caloric testing is not done. 0 = Normal 1 = Partial gaze palsy; gaze is abnormal in one or both eyes, but forced deviation and total gaze paresis is not present 2 = Forced deviation, or total gaze paresis not overcome by the oculocephalic maneuver . . .. . ...
Visual: Visual fields (upper and lower quadrants)
are tested by confrontation, using finger counting or visual threat, as appropriate. Patients may be encouraged, but if they look at the side of the moving fingers appropriately, this can be scored as normal. . . .. . ...
4.
Facial palsy 0 = Normal symmetrical movements 1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling) 2 = Partial paralysis (total or near-total paralysis of lower face) 3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower face)
. . .. . ... 
Motor arm
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. Extinction and inattention (formerly neglect) 0 = No abnormality 1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities 2 = Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients to only one side of space
future vascular events. High levels of CRP may be associated with poor outcome because they reflect either an inflammatory reaction or tissue damage [3] . It is not clear whether this is due to a direct effect or rather an epiphenomenon. Elevated serum levels of CRP are found in up to three quarters of patients with ischemic stroke [4] . Increases in CRP may reflect a systemic inflammatory response following stroke, the extent of tissue injury, or concurrent infections. Moreover, in animal models of focal cerebral ischemia, CRP increases secondary brain damage through activation of the complement system [5] . Less evidence is available for hemorrhagic stroke. Plasma CRP was seen to increase shortly after admission and was related to hematoma volume at later time points in hemorrhagic stroke [6] . This was attributed to inflammatory response to the hematoma [6] .
The role of CRP as a marker during and after stroke is less extensively studied in comparison to coronary artery disease. The Rotterdam study shows that although high CRP is associated with the risk for future stroke, it is not useful for individual stroke prediction [7] . On the other hand, the Framingham study shows that high CRP is associated with a greater risk for ischemic stroke or TIA [8] .
Several studies have assessed the value of CRP in the very early phases of stroke as a prognostic factor of functional outcome. Many of these studies evaluated only the relation between CRP and mortality instead of functional outcome. The findings were inconclusive; some found a positive association but others did not [9, 10] .
In search for further clarification of its role in cerebrovascular stroke, we sought to evaluate CRP level as an early prognostic factor of functional outcome after stroke, as it is an easily measured and a readily available inflammatory marker.
Aim of the study
This study was intended to evaluate the role of serum CRP assay within 24 h of stroke onset as a biomarker for predicting disease severity and short term outcome (within 1 week).
Patients and methods
This prospective study included patients admitted with firstever acute stroke within the first 24 h of onset to the general intensive care unit of the Damietta general hospital in the period from May 2012 to November 2012. We excluded patients admitted more than 24 h after symptoms onset, patients with recent history of traumatic brain injury, acute coronary syndrome, cerebro-vascular events, autoimmune disease, liver cell failure, and chronic renal failure.
The study protocol was approved by the institutional review board at Cairo University together with representatives of study conduction site, and written informed consent to participate and publish data were obtained from all participating patients or first degree relatives.
Patients included in the study were subjected to full history taking with special emphasis on smoking index (number of cigarettes/day times number of years), hypertension (defined as Table 2 The main items of the mR.
Score Description 0
No symptoms at all 1 No significant disability despite symptoms; able to carry out all usual duties and activities 2 Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3
Moderate disability; requiring some help, but able to walk without assistance 4
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5
Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6 Dead [11, 12] . Table 1 shows the main items of the NIHSS.
Seven days following the onset of stroke, we evaluated the outcome of patients using two different scores including modified Rankin Scale (mRS) [13] [14] [15] and Barthel ADL index (BI) [16] . Poor outcome was considered to be >2 by mRS score and <95 by BI. Tables 2 and 3 show the main items of the mRS and BI, respectively. A brain CT scan was done on admission to all patients to differentiate between ischemic and hemorrhagic stroke.
Blood samples were withdrawn on admission for routine laboratory tests and for CRP level assay. Three ml of venous blood was taken through a venipuncture and sent coded by the patient's number to the laboratory. The lab was blinded to the samples. The CRP assay was done using solid phase enzyme-linked immunosorbent assay. Normal reference of CRP was less than 5 mg/L.
Statistical methods
Data were prospectively collected and coded prior to analysis using the professional statistical Package for Social Science (SPSS version 16). The description of data was in the form of mean (±) SD for quantitative data and frequency and proportion for qualitative data. Student-t Test (t) was used for comparison between two groups regarding normally distributed (parametric) quantitative data. Chi-Square Test (x 2 ) was used for comparison between two groups regarding qualitative data. Spearman correlation coefficient test (r) was used to test a positive or negative relationship between two variables. Results were considered significant if P 6 0.05. A receiver operating characteristic (ROC) analysis was performed to define a cut-off value of serum CRP for severe stroke and poor outcome prediction and the associated specificity and sensitivity levels.
Results
This is a prospective study involving 50 patients admitted with acute stroke within 24 h of onset. The mean age of our population was 59.5 ± 8.6 years ranging from 45 to 75 years. According to admission CT brain, our patients were classified into two groups; Group A included 25 patients with acute ischemic stroke (13 M, mean age 58.7 ± 9.3 years old) and Group B involved 25 patients with hemorrhagic stroke (13 M, mean age 60.3 ± 8 years old). Table 4 shows some of the general characteristics of our population. Twenty patients from hemorrhagic stroke group had spontaneous intracerebral hemorrhage while five had subarachnoid hemorrhage.
Patients were categorized as mild stroke (NIHSS 0-7), moderate (NIHSS 8-14), or severe stroke (NIHSS >14). Patient outcome was measured by mRS and BI seven days after stroke onset. Poor outcome was defined as mRS > 2 or BI < 95.
Severity of stroke assessed by NIHSS revealed a mean score of 13 ± 14 with 15 patients (30%) stratified as severe, 5 patients (10%) as moderate, and 30 patients (60%) as mild ( Fig. 1) .
Outcomes assessed 7 days after admission by mRS revealed a poor outcome in 22 patients (44%); however, outcome evaluation by BI revealed a poor outcome in 32 patients (64%). The mean mRS for the whole population was 2.7 ± 2.2 and the mean BI was 60.7 ± 41 ( Fig. 1) . Figure 1 Presentation severity according to NIHSS and outcome according to mRS and BI in the study population.
There was a strong positive correlation between disease severity assessed by NIHSS and outcome assessed by mRS (r = 0.9, P < 0.001) and a strong negative correlation with the outcome assessed by BI (r = À0.96, P < 0.001).
Serum CRP level on admission was positively correlated with NIHSS (r = 0.337, P = 0.02), with mRS (r = 0.276, P = 0.05), and negatively correlated with BI (r = À0.375, P = 0.007).
The demographic characteristics of both groups of the study are shown in Table 5 .
Serum CRP level in group A was positively correlated with NIHSS (r = 0.54, P = 0.006) (Fig. 2 ). Serum CRP level was 14.4 ± 6 mg/L in patients with severe ischemic stroke compared to 7.7 ± 4.5 mg/L in patients with mild and moderate presentation (P = 0.01). We detected a CRP level of 10.25 mg/L to predict severe ischemic stroke with a sensitivity of 80% and a specificity of 75%. Patients of group B with hemorrhagic stroke showed that the admission CRP was however, not correlated with stroke severity. We could not define any correlation between serum CRP level and NIHSS (r = 0.31, P = 0.1) ( Fig. 3) .
In ischemic stroke, Serum CRP on admission correlated positively with mRS (r = 0.56, P = 0.004) and negatively with BI (r = À0.66, P < 0.001) ( Fig. 4) . Mean serum CRP level in patients with poor outcomes according to mRS was 13 ± 6.3 mg/ L compared to 7.1 ± 4 mg/L for patients with favorable outcomes (P = 0.009) and it was 11.8 ± 5.4 mg/L in patients with poor outcomes according to BI compared to 4.9 ± 1.6 mg/L in patients with favorable outcomes (P = 0.001) ( Table 6 ). Using ROC analysis, we detected a cut-off level of serum CRP level on admission of 10.25 mg/L to predict poor prognosis using mRS with a sensitivity of 75% and a specificity of 82% and a level of 6.95 mg/L to predict poor prognosis using BI with a sensitivity of 80% and a specificity of 90%. In hemorrhagic stroke, there was no correlation between CRP and mRS (r = 0.22, P = 0.3) or BI (r = À0.24, P = 0.24) ( Fig. 5 ). Serum CRP level was 6.9 ± 4.6 mg/L in patients with poor outcome using mRS in hemorrhagic stroke compared to 5.3 ± 2.5 mg/L in patients with favorable outcome (P = 0.3) and it was 6.3 ± 4.4 mg/L in patients with poor outcome using BI compared to 5.8 ± 2.6 mg/L in patients with favorable outcome (P = 0.7) ( Table 6 ).
Disease severity assessed by NIHSS was positively correlated with mRS in both groups (r = 0.83, P < 0.001 and r = 0.95, P < 0.001 for both groups, respectively) and negatively correlated with BI (r = À0.93, P < 0.001 and r = À0.97, P < 0.001, respectively). In ischemic stroke, NIHSS was 25 ± 14.6 and 15.1 ± 15 in patients with poor outcome assessed by mRS and BI, respectively, compared to 3.2 ± 1.1 and 2.7 ± 1 for patients with favorable outcomes (P < 0.001 and P = 0.01 for mRS and BI, respectively). In hemorrhagic stroke, it was 26.5 ± 12.1 in patients with poor outcomes using mRS and it was 22.8 ± 13.7 in patients with poor outcomes using BI compared to 2.3 ± 2.5 and 1 ± 1.4 in patients with favorable outcomes using mRS and BI, respectively (P < 0.001 for both).
Comparing both groups together, CRP was significantly higher in ischemic stroke than in hemorrhagic stroke. CRP Figure 2 Correlation between CRP and NIHSS in ischemic stroke. was 9 ± 5.5 mg/L in ischemic stroke compared to 6.2 ± 3.8 mg/L in hemorrhagic stroke (P = 0.039) ( Fig. 6 ).
Discussion
Stroke is the third most common cause of death and the first leading cause of disability in developed and developing countries [17] . C-reactive protein is a glycoprotein produced by the liver, and is normally absent in blood. The presence of acute inflammation with tissue destruction within the body stimulates its production. The CRP typically rises within 6 h of the start of inflammation, allowing the inflammation to be confirmed [18] . Atherothrombosis is the leading cause of stroke [19] and it is now recognized that inflammation is central to the initiation, development and rupture of atherosclerotic plaques [20] . The recruitment of immune cells, such as macrophages and T-cells, to plaques leads to the secretion of multiple inflammatory mediators, including pro-inflammatory cytokines, free radicals and proteases that ultimately promote plaque rupture and thrombosis [20] . Brain damage whether ischemic or hemorrhagic stimulates the mobilization and migration of peripheral immune cells, particularly neutrophils and macrophages, into the brain and induces systemic inflammatory response [21, 22] . We intended to evaluate the value of early serum CRP level on admission as a biomarker for predicting stroke severity and short term outcome in patients admitted with stroke.
We found in our study that the serum CRP is a predictor for severity and outcome in ischemic stroke but not in hemorrhagic stroke. It was positively correlated with NIHSS and mRS and negatively correlated with BI in ischemic stroke. We found a serum CRP level of 10.25 mg/L to be 80% sensitive and 75% specific to address severe ischemic stroke and to be 75% sensitive and 82% specific to address poor outcome using mRS.
The NIHSS was used in this study to evaluate the stroke severity and was developed and validated for assessing the initial stroke severity [11, 23] . Many studies showed that it is predictive of stroke outcomes [12, [24] [25] [26] . Our study showed that the NIHSS is a strong predictor for poor outcome in stroke patients whether ischemic or hemorrhagic, thus was in agreement with other studies [12, [24] [25] [26] . A study of ischemic stroke patients identified admission stroke severity as measured by NIHSS score as the strongest predictor of 3-month mortality [27] and another one concluded that it was the only independent predictor of 30-day mortality [26] . All of these studies evaluated the NIHSS in ischemic stroke. In our study, it was a predictor for outcome in both hemorrhagic and ischemic strokes.
We evaluated the clinical and biomarker variables in the whole population and then in two groups of hemorrhagic and ischemic stroke patients. Serum CRP level was found to be significantly correlated with the stroke severity and outcome irrespective of the type of the stroke. While subanalysing each group separately, we found that the serum CRP level, measured within 24 h of stroke onset, was significantly correlated with disease severity and outcome in ischemic but not in hemorrhagic stroke. The significant correlation between the CRP and the severity and outcome in the whole population could hence be explained by the strong correlation in the ischemic stroke sub-population.
Many investigators have found a wide range of increase in CRP after stroke [28, 29] . Di Napoli et al. found that CRP concentration increased in the first 24 h following stroke; this increment was associated with the size of the infarction, so mounting CRP levels in the first 24 h were synchronized to poor prognosis [29] . However, the same investigator in a later work concluded that there is insufficient evidence to justify the routine use of CRP for either primary or secondary risk stratification for cerebrovascular disease alone [30] . Some other investigators also reported an association with mortality, but functional outcome was not assessed [9] .
The association between high CRP and a high stroke severity remains unexplained. Atherothrombosis of the cerebral vessels is considered an inflammatory disorder with acute phase reactant proteins produced in the first few hours [18] . The degree of inflammation determined by elevated CRP levels has been associated with an increased risk of vascular complications [31] . There is a distinct possibility that elevated CRP is a direct response to the extent of cerebral tissue injury [32] .
As an inflammatory marker, it is possible that high CRP is associated with underlying processes that cause more severe strokes. Another link is the activation of coagulation by the elevated CRP levels through the important role of tissue factor expression [33] . Previous data showed that activation of coagulation factors in stroke patients increased mortality, and fibrinogen has a putative role [34, 35] .
Interestingly, studies have shown that CRP itself may contribute to secondary brain damage after focal cerebral ischemia, possibly via a complement-mediated exacerbation of tissue injury [36] . It is therefore conceivable that increased levels of CRP following stroke are not only a consequence of brain infarction, but contribute to ischemic damage as well.
Whether high CRP causes more severe strokes or vice versa needs to be further studied in larger population-based cohort studies, or in clinical studies with very early measurements. Precise knowledge of the possible triggers of inflammation and the determinants of its individual response may open novel therapeutic avenues. The absence of a crucial role of the inflammatory process in the pathogenesis of hemorrhagic stroke could explain the lack of the prognostic value of CRP in this subgroup of patients. Contrary to this, some studies revealed an association between elevated CRP and outcome in hemorrhagic stroke including an association even with hematoma size in intracerebral hemorrhage [6] and an association with the occurrence of vasospasm in aneurysmal subarachnoid hemorrhage [37, 38] . Spontaneous intracerebral hemorrhage was seen to precipitate a complex cascade of cerebral and systemic inflammatory response [39] . The acutely injured brain releases large amount of interleukin-6 (IL-6) that is correlated with severity of brain injury and prognosis [40] . Furthermore, IL-6 is a major stimulus for hepatic production of CRP. The inflammatory reaction in hemorrhagic stroke appears to be a response to hemorrhage rather than a pathogenesis as in ischemic stroke. Accordingly, in acute ischemic stroke the CRP response appears to be triggered quite rapidly [41] . This might explain the lack of relation between CRP and outcome in hemorrhagic stroke as we measured serum CRP early on hospital admission only.
We found in our study that the serum CRP level was significantly higher in ischemic stroke compared to hemorrhagic stroke. Our results were in agreement with the results of other researchers [42, 43] . Again, this could explain the early role played by the inflammatory process in the pathogenesis of ischemic stroke more than in hemorrhagic stroke.
Our study has few limitations. Although the use of high sensitivity CRP would have been more sensitive than the regular CRP, however, we thought to evaluate the commonly present, readily available marker in most ICUs in our country as a prognostic marker for cerebrovascular accidents. One limitation is that we did not correlate the size of the hemorrhage on CT examination with CRP, however, this could have been an addition only if we have found a clinical correlation of the hemorrhagic stroke with CRP, which we did not find. Moreover, our study mainly aimed at finding a correlation between the CRP and the clinical outcome rather than the radiologic findings. Another limitation is the use of single CRP measurement rather than multiple measurements which could have been more informative about the later stages of the stroke, however, our study aimed at evaluating the early predictive value of the biomarker.
Conclusion
Assessing CRP on admission is a predictor for severe disease and poor outcome in ischemic, but not in hemorrhagic stroke.
